Stock Market Today (14 August 2026): Tata Motors Profit Falls 80%, Zee Jumps 7% on SAT Relief

Tata Motors set the tone for a rough patch in the auto space today, with profit collapsing 80% on weak JLR performance even as revenue grew. The Nifty slipped below 24,350 as metals extended a two-day decline, with NALCO among the sharpest fallers on softer aluminium prices — a sharp reversal from the rally the stock enjoyed just days ago on global supply-cut news. On the brighter side, Zee Entertainment jumped 7% after the Securities Appellate Tribunal handed it relief on its long-running SEBI dispute, Voltas and Honasa Consumer posted strong Q1 beats, and Natco Pharma balanced a weak quarter with a fresh fundraising plan and an FDA approval.

Tata Motors Profit Collapses 80% on Weak JLR Show

Tata Motors fell 5% after posting a Q1 profit decline of 80%, even as revenue rose 9.3% to ₹95,800 crore and wholesale volumes climbed 23%. The miss was pinned largely on margin pressure at Jaguar Land Rover, and brokerages responded with a wave of target cuts. HSBC trimmed its target to ₹360 on commodity headwinds, Citi kept a Sell rating at ₹305 after the miss, and Motilal Oswal stuck with Sell at ₹310. CLSA was the outlier, setting a ₹452 target and pointing to JLR margins and strong underlying demand as reasons for a more constructive view.

Zee Entertainment Jumps 7% as SAT Grants Relief

Zee Entertainment had a considerably better day, rising as much as 7% after the Securities Appellate Tribunal stayed the SEBI order that had restricted the company's market access. The tribunal also cleared Zee's ₹3,144 crore fundraising plan and allowed it to issue promoter warrants and use mutual fund units for dividend payments. Management said it remains compliant with SEBI requirements and denied withholding any price-sensitive information, a formal response to the scrutiny that has weighed on the stock through much of this earnings season.

Voltas Surges 52% on Profit Growth, Announces Atomberg JV

Voltas posted a 52% jump in Q1 profit to ₹214 crore and used the results to announce a joint venture with Atomberg aimed at strengthening air-conditioning technology and component localization. The combination of a strong quarter and a forward-looking partnership gave the stock a clean, uncomplicated positive story on a day when several other large names were dealing with more mixed narratives.

Honasa Consumer Beats Estimates, Brokerages Split on Margins

Honasa Consumer, the company behind Mamaearth, reported profit up 117% to ₹90 crore with revenue rising 27%. Jefferies upgraded the stock to Buy and raised its target to ₹650, citing strong growth and margins. JPMorgan was more cautious, setting a ₹410 target while flagging margin pressure despite the revenue growth, and CLSA kept a Hold rating at ₹505. The wide gap between Jefferies' bullish call and JPMorgan's more conservative one suggests the market hasn't fully settled on how sustainable this quarter's margin performance is.

Natco Pharma Slides on Weak Quarter, Cushioned by Fundraise and FDA Nod

Natco Pharma fell 6.4% after Q1 profit slumped 57% and revenue fell 43%, with EBITDA down 67% and margins compressing sharply to 25.4-30.9% depending on the segment reported. The company tried to offset the disappointment with a ₹1.50 dividend declaration and board approval for a ₹2,000 crore fundraising plan. Separately, the FDA cleared Natco's Eribulin injection, an approval that could support the US pipeline even as the current quarter's numbers disappointed.

Cholamandalam Posts Strong Growth, Though Figures Vary Across Filings

Cholamandalam Investment and Finance reported a strong quarter, with revenue up 19% to ₹111 billion. Profit growth was reported at two different figures across filings — a 39% rise to ₹806 crore in one release and a 42% rise to ₹1,789 crore in another — a discrepancy likely tied to different reporting bases that the company would do well to clarify. Either reading points to a healthy quarter for the non-bank lender.

NALCO Extends Slide as Aluminium Prices Pull Back

NALCO fell as much as 10% over two sessions, with the Nifty Metal index down 2.7% over the same period, as aluminium prices retreated from the highs that had driven the stock's rally earlier in the week. The reversal is a reminder of how tightly NALCO's near-term price action is linked to global aluminium supply and demand headlines rather than company-specific developments.

Sector Watch: Defense, Capital Goods and Pharma

Defense and capital goods names had a strong session. Bharat Dynamics posted a sixfold jump in Q1 profit with revenue up 128%, and Praj Industries jumped 8% on a 119% profit surge alongside a ₹3.60 dividend declaration. Solar Industries beat Q1 estimates with international growth at 65%, though brokerages remained sharply divided — Goldman Sachs set a ₹20,180 Buy target while Kotak retained a Sell at ₹11,200, one of the widest target spreads of the week. Ashok Leyland's profit rose a modest 2.6% with margins dipping to 10.5%, even as the company committed ₹825 crore toward Optare and Hinduja Housing Finance.

In pharma, Alkem Labs' profit fell 22% despite revenue growth of 11%, with the company flagging FDA status at its Daman facility as a risk while still committing ₹75 crore to Baddi expansion. Patanjali Foods, by contrast, posted an 86% profit surge with revenue up 27% and announced fresh dividends, one of the stronger consumer prints of the day.

Market Outlook

Today's session reinforced how uneven this earnings season has become. Tata Motors and Natco Pharma both disappointed on profit even as their underlying businesses showed pockets of strength, while Voltas, Honasa and Bharat Dynamics delivered cleaner beats that the market rewarded without much hesitation.

Zee Entertainment's regulatory relief removes a meaningful overhang that has weighed on the stock for weeks, and could allow investor focus to shift back toward its underlying media business. NALCO's reversal is a caution against reading too much into any single day's commodity-driven rally, and the wide brokerage split on Solar Industries suggests valuation, not the quarter itself, is where the real disagreement lies.